$AGEN
AGENUS INC Stock $agen

$agen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024031620 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$28.01M	$83.80M	$156.3M
YoY Change	22.28%	195.22%	59.47%
Cost Of Revenue	$107.0K	$260.0K	$3.111M
YoY Change	-95.34%	-96.62%	-70.56%
Gross Profit	$27.90M	$83.54M	$153.2M
YoY Change	35.37%	303.72%	75.18%
Gross Profit Margin	99.62%	99.69%	98.01%
Selling, General & Admin	$16.86M	$21.18M	$78.74M
YoY Change	-7.58%	-15.41%	-2.8%
% of Gross Profit	60.42%	25.35%	51.4%
Research & Development	$43.93M	$66.72M	$234.6M
YoY Change	-23.1%	25.23%	25.65%
% of Gross Profit	157.45%	79.87%	153.11%
Depreciation & Amortization	$3.374M	$5.201M	$11.90M
YoY Change	31.69%	175.33%	153.19%
% of Gross Profit	12.09%	6.23%	7.77%
Operating Expenses	$43.93M	$87.90M	$234.6M
YoY Change	-23.1%	12.24%	25.65%
Operating Profit	-$32.88M	-$4.359M	-$159.5M
YoY Change	-39.49%	-92.44%	-11.08%
Interest Expense	-$29.47M	-$44.02M	-$97.93M
YoY Change	77.59%	152.13%	58.29%
% of Operating Profit
Other Income/Expense, Net	-$1.106M	-$201.0K	$37.00K
YoY Change	-2865.0%	-106.89%	-99.71%
Pretax Income	-$63.45M	-$48.58M	-$257.4M
YoY Change	-10.49%	-34.44%	11.61%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$63.45M	-$46.34M	-$257.4M
YoY Change	-10.49%	-34.86%	11.61%
Net Earnings / Revenue	-226.58%	-55.3%	-164.69%
Basic Earnings Per Share	-$3.04		-$0.69
Diluted Earnings Per Share	-$3.04	-$0.12	-$0.69
COMMON SHARES
Basic Shares Outstanding	418.9M	381.5M	357.9K
Diluted Shares Outstanding	20.37M		357.9K

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.86M	$76.11M	$76.11M
YoY Change	-72.07%	-60.64%	-60.64%
Cash & Equivalents	$52.86M	$76.11M	$76.11M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$3.125M	$2.372M	$10.47M
YoY Change	-19.79%	-25.74%	-38.49%
Inventory
Prepaid Expenses	$3.895M	$8.098M
Receivables	$476.0K	$25.84M	$25.84M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$60.35M	$112.4M	$112.4M
YoY Change	-70.66%	-47.25%	-47.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$130.3M	$133.4M	$163.0M
YoY Change	-7.19%	0.3%	-0.77%
Goodwill	$24.70M	$24.72M
YoY Change	-3.61%	-2.92%
Intangibles	$4.230M	$4.411M
YoY Change	-25.27%	-29.17%
Long-Term Investments
YoY Change
Other Assets	$7.609M	$9.336M	$9.336M
YoY Change	72.19%	109.66%	109.66%
Total Long-Term Assets	$196.2M	$201.5M	$201.5M
YoY Change	-5.29%	0.53%	0.53%
TOTAL ASSETS
Total Short-Term Assets	$60.35M	$112.4M	$112.4M
Total Long-Term Assets	$196.2M	$201.5M	$201.5M
Total Assets	$256.6M	$313.9M	$313.9M
YoY Change	-37.86%	-24.09%	-24.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$50.69M	$61.45M	$61.45M
YoY Change	8.39%	50.09%	50.09%
Accrued Expenses	$41.29M	$45.28M	$47.87M
YoY Change	23.43%	18.36%	19.07%
Deferred Revenue	$13.00K	$18.00K
YoY Change	-99.87%	-99.85%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.58M	$146.0K	$10.60M
YoY Change	1228.28%	-74.61%	24.35%
Total Short-Term Liabilities	$256.0M	$255.9M	$255.9M
YoY Change	34.1%	35.43%	35.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$12.77M	$17.49M
YoY Change	-100.0%	1.46%	-29.64%
Other Long-Term Liabilities	$2.732M	$5.420M	$188.9M
YoY Change	-80.36%	-60.8%	-25.82%
Total Long-Term Liabilities	$2.732M	$18.19M	$206.4M
YoY Change	-89.71%	-31.13%	-26.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$256.0M	$255.9M	$255.9M
Total Long-Term Liabilities	$2.732M	$18.19M	$206.4M
Total Liabilities	$258.7M	$274.1M	$474.2M
YoY Change	18.99%	27.27%	-0.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.000B	-$1.960B
YoY Change	11.11%	14.62%
Common Stock	$210.0K	$3.944M
YoY Change	-93.85%	29.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$201.4M	-$160.3M	-$160.3M
YoY Change
Total Liabilities & Shareholders Equity	$256.6M	$313.9M	$313.9M
YoY Change	-37.86%	-24.09%	-24.09%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$63.45M	-$46.34M	-$257.4M
YoY Change	-10.49%	-34.86%	11.61%
Depreciation, Depletion And Amortization	$3.374M	$5.201M	$11.90M
YoY Change	31.69%	175.33%	153.19%
Cash From Operating Activities	-$38.19M	-$40.40M	-$224.2M
YoY Change	-34.75%	-14.65%	27.84%
INVESTING ACTIVITIES
Capital Expenditures	$35.00K	$223.0K	$9.954M
YoY Change	-98.1%	-98.45%	-81.24%
Acquisitions
YoY Change
Other Investing Activities	$264.0K	$3.047M	$13.35M
YoY Change	-102.74%	-61.74%	-31.35%
Cash From Investing Activities	$229.0K	$2.824M	$3.400M
YoY Change	-101.99%	-144.24%	-110.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.83M	7.315M	119.9M
YoY Change	-73.64%	-69.23%	25.08%
NET CHANGE
Cash From Operating Activities	-38.19M	-40.40M	-224.2M
Cash From Investing Activities	229.0K	2.824M	3.400M
Cash From Financing Activities	14.83M	7.315M	119.9M
Net Change In Cash	-23.25M	-30.26M	-101.6M
YoY Change	67.84%	1.05%	-10.32%
FREE CASH FLOW
Cash From Operating Activities	-$38.19M	-$40.40M	-$224.2M
Capital Expenditures	$35.00K	$223.0K	$9.954M
Free Cash Flow	-$38.23M	-$40.62M	-$234.2M
YoY Change	-36.68%	-34.14%	2.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001098972
CY2023	dei	Entity Registrant Name EntityRegistrantName	AGENUS INC
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201704Member
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://www.agenusbio.com/20231231#UsefulLifeIndefiniteMember
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-29089
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1562417
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 Forbes Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
CY2023	dei	City Area Code CityAreaCode	781
CY2023	dei	Local Phone Number LocalPhoneNumber	674-4400
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $.01 Par Value
CY2023	dei	Trading Symbol TradingSymbol	AGEN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	583500000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	418920071
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76110000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178674000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	14684000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25836000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2741000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8098000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13829000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2372000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3194000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	112416000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	213122000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61943000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54075000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133421000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133017000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29606000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31269000
CY2023Q4	us-gaap	Goodwill Goodwill	24723000
CY2022Q4	us-gaap	Goodwill Goodwill	25467000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17688000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16148000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4411000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6228000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9336000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4453000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-160331000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-61278000
CY2023Q4	us-gaap	Assets Assets	313913000
CY2022Q4	us-gaap	Assets Assets	413556000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	146000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	575000
CY2023Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Payment Current LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesPaymentCurrent	132502000
CY2022Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Payment Current LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesPaymentCurrent	83510000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12269000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2587000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1943000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	61446000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	40939000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45283000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	38259000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13915000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11457000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	255897000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	188952000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12768000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12584000
CY2023Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Payment Non Current LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesPaymentNonCurrent	124556000
CY2022Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Payment Non Current LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesPaymentNonCurrent	187753000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1143000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1143000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62511000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	63326000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5420000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14700000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	394373240
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	305573397
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3944000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3056000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1792348000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1644658000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-955000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	915000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1955668000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1709907000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	11949000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	6376000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-148382000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-54902000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	313913000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	413556000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156314000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98024000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295665000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	3111000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	10568000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3470000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234569000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	186691000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	178608000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	78739000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	81007000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	76359000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	556000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	815000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-11481000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-159549000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-179427000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	25747000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6197000
CY2022	agen	Loss On Modification Of Debt LossOnModificationOfDebt	-1937000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	37000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12571000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5051000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-97925000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-61863000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-65719000
CY2023	us-gaap	Profit Loss ProfitLoss	-257437000
CY2022	us-gaap	Profit Loss ProfitLoss	-230656000
CY2021	us-gaap	Profit Loss ProfitLoss	-28724000
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	213000
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	212000
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	211000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11676000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10582000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4798000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-245974000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-220286000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24137000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	357889
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	357889
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	281743
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	281743
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	228919
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	228919
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1870000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-577000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1280000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1870000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-577000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1280000
CY2023	agen	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-247844000
CY2022	agen	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-220863000
CY2021	agen	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-25417000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-211498000
CY2021	us-gaap	Profit Loss ProfitLoss	-28724000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1280000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19134000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	197648000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	26917000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	10000000
CY2021	agen	Sale Of Subsidiary Shares In Initial Public Offering SaleOfSubsidiarySharesInInitialPublicOffering	22997000
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	70000
CY2021	agen	Shares Issued To Payroll In Value SharesIssuedToPayrollInValue	171000
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	216000
CY2021	agen	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	9132000
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1478000
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1648000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47909000
CY2022	us-gaap	Profit Loss ProfitLoss	-230656000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-577000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18395000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99211000
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2332000
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	138000
CY2022	agen	Stock Issued During Period Value Director Deferred Shares StockIssuedDuringPeriodValueDirectorDeferredShares	19000
CY2022	agen	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	898000
CY2022	agen	Stock Issued During Period Value Issued For Milestone Achievement StockIssuedDuringPeriodValueIssuedForMilestoneAchievement	500000
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	294000
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	3017000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	21366000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6494000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10824000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12249000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10368000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-21832000
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	20613000
CY2022	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	3618000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-54902000
CY2023	us-gaap	Profit Loss ProfitLoss	-257437000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1870000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22351000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	133157000
CY2023	agen	Shares Issued To Payroll In Value SharesIssuedToPayrollInValue	146000
CY2023	agen	Stock Issued During Period Value Director Deferred Shares StockIssuedDuringPeriodValueDirectorDeferredShares	983000
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	690000
CY2023	agen	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	807000
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	1011000
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	3233000
CY2023	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	4055000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-148382000
CY2023	us-gaap	Profit Loss ProfitLoss	-257437000
CY2022	us-gaap	Profit Loss ProfitLoss	-230656000
CY2021	us-gaap	Profit Loss ProfitLoss	-28724000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13588000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6946000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6788000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	22869000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18337000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	19577000
CY2023	agen	Non Cash Royalty Revenue NonCashRoyaltyRevenue	114572000
CY2022	agen	Non Cash Royalty Revenue NonCashRoyaltyRevenue	45285000
CY2021	agen	Non Cash Royalty Revenue NonCashRoyaltyRevenue	44355000
CY2023	agen	Non Cash Interest Expense NonCashInterestExpense	100551000
CY2022	agen	Non Cash Interest Expense NonCashInterestExpense	62955000
CY2021	agen	Non Cash Interest Expense NonCashInterestExpense	64619000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1408000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	16196000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3301000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6111000
CY2022	agen	Gain Loss On Partial Forgiveness Of Liability GainLossOnPartialForgivenessOfLiability	2791000
CY2022	agen	Loss On Modification Of Debt LossOnModificationOfDebt	-1937000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6197000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-556000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-815000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	11481000
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	2007000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23461000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-122000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	394000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-6032000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11865000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5129000
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2034000
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1062000
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1545000
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-13937000
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-7850000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-224202000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-175373000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10145000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3363000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	21998000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5656000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9954000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53062000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33814000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	14647000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	24629000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	14992000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	30000000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	25000000
CY2023	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5396000
CY2023	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	34000
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2917000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3400000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33610000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43150000
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	133157000
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	99211000
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	197648000
CY2021	agen	Proceeds From Sale Of Subsidiary Shares In Initial Public Offering ProceedsFromSaleOfSubsidiarySharesInInitialPublicOffering	22997000
CY2023	agen	Proceeds From Employee Stock Purchases And Option Exercises ProceedsFromEmployeeStockPurchasesAndOptionExercises	807000
CY2022	agen	Proceeds From Employee Stock Purchases And Option Exercises ProceedsFromEmployeeStockPurchasesAndOptionExercises	898000
CY2021	agen	Proceeds From Employee Stock Purchases And Option Exercises ProceedsFromEmployeeStockPurchasesAndOptionExercises	9132000
CY2023	agen	Purchase Of Treasury Shares To Satisfy Tax Withholdings PurchaseOfTreasurySharesToSatisfyTaxWithholdings	4566000
CY2022	agen	Purchase Of Treasury Shares To Satisfy Tax Withholdings PurchaseOfTreasurySharesToSatisfyTaxWithholdings	3789000
CY2021	agen	Purchase Of Treasury Shares To Satisfy Tax Withholdings PurchaseOfTreasurySharesToSatisfyTaxWithholdings	1654000
CY2023	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	606000
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1542000
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	462000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	8926000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	490000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	855000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119866000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95830000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	225264000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-628000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-104000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-164000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-101564000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-113257000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	192095000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	181343000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	294600000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	102505000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79779000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	181343000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	294600000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3168000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1143000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1152000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4580000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5363000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023	agen	Stock Issued For Subsidiary Employee Bonus StockIssuedForSubsidiaryEmployeeBonus	1011000
CY2022	agen	Stock Issued For Subsidiary Employee Bonus StockIssuedForSubsidiaryEmployeeBonus	294000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	10000000
CY2023	agen	Insurance Financing Agreement InsuranceFinancingAgreement	707000
CY2022	agen	Insurance Financing Agreement InsuranceFinancingAgreement	1377000
CY2021	agen	Insurance Financing Agreement InsuranceFinancingAgreement	1630000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	318000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9206000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1649000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	4812000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	25027000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	762000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	76100000
CY2022	agen	Decrease In Cash And Cash Equivalents And Short Term Investments DecreaseInCashAndCashEquivalentsAndShortTermInvestments	-117200000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1960000000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	76100000
CY2023Q3	agen	Percentage Of Reduced Workforce PercentageOfReducedWorkforce	0.25
CY2023	agen	Number Of Subsidiaries Owned Less Than Hundred Percentage NumberOfSubsidiariesOwnedLessThanHundredPercentage	2
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6228000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:2.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(c) Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2023	us-gaap	Depreciation Depreciation	11900000
CY2022	us-gaap	Depreciation Depreciation	4700000
CY2021	us-gaap	Depreciation Depreciation	4600000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13100000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13600000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-100000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000000
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2200000
CY2023Q4	us-gaap	Reporting Unit Zero Or Negative Carrying Amount Amount Of Allocated Goodwill ReportingUnitZeroOrNegativeCarryingAmountAmountOfAllocatedGoodwill	24100000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2023Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adoption Date ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate	2023-01-01
CY2023Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Immaterial Effect ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect	true
CY2022Q4	us-gaap	Goodwill Goodwill	25467000
CY2023	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	805000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	61000
CY2023Q4	us-gaap	Goodwill Goodwill	24723000
CY2023	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	2057000
CY2023	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	2057000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	22099000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17688000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4411000
CY2022	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	2036000
CY2022	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	2036000
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	22376000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16148000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	600000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	500000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	500000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	400000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	300000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	70500000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	164700000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3700000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2700000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2700000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76110000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178674000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291931000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3669000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2669000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2669000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79779000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	181343000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	294600000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	195364000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	187092000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61943000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54075000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133421000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133017000
CY2023	agen	Capitalized Domestic Expenses Amortization Period CapitalizedDomesticExpensesAmortizationPeriod	P5Y
CY2023	agen	Capitalized Foreign Expenses Amortization Period CapitalizedForeignExpensesAmortizationPeriod	P15Y
CY2023Q4	agen	Deferred Tax Assets Capitalized Research Expenditures DeferredTaxAssetsCapitalizedResearchExpenditures	70900000
CY2022Q4	agen	Deferred Tax Assets Capitalized Research Expenditures DeferredTaxAssetsCapitalizedResearchExpenditures	41500000
CY2023Q4	agen	Deferred Tax Assets Operating Loss Carry Forwards Federal And State DeferredTaxAssetsOperatingLossCarryForwardsFederalAndState	191671000
CY2022Q4	agen	Deferred Tax Assets Operating Loss Carry Forwards Federal And State DeferredTaxAssetsOperatingLossCarryForwardsFederalAndState	175058000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	7093000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	7203000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8348000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9979000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5083000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6163000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	24563000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	31070000
CY2023Q4	agen	Deferred Tax Assets Interest Expense Carryforward DeferredTaxAssetsInterestExpenseCarryforward	12183000
CY2022Q4	agen	Deferred Tax Assets Interest Expense Carryforward DeferredTaxAssetsInterestExpenseCarryforward	16140000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	46025000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	51959000
CY2023Q4	agen	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	17709000
CY2022Q4	agen	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	19429000
CY2023Q4	agen	Deferred Tax Assets Capitalized Research Expenditures DeferredTaxAssetsCapitalizedResearchExpenditures	70879000
CY2022Q4	agen	Deferred Tax Assets Capitalized Research Expenditures DeferredTaxAssetsCapitalizedResearchExpenditures	41513000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8773000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6301000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	392327000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	364815000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	376483000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	347869000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15844000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16946000
CY2023Q4	agen	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets Foreign DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssetsForeign	462000
CY2022Q4	agen	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets Foreign DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssetsForeign	854000
CY2023Q4	agen	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	6761000
CY2022Q4	agen	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	7490000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8589000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8479000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	144000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1034000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15956000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17857000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	112000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	911000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-54096000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-48438000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5976000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	27647000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	50039000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5916000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1674000
CY2023	agen	Effective Income Tax Rate Reconciliation Nontaxable Liquidation Of Subsidiaries EffectiveIncomeTaxRateReconciliationNontaxableLiquidationOfSubsidiaries	1925000
CY2022	agen	Effective Income Tax Rate Reconciliation Loan Forgiveness EffectiveIncomeTaxRateReconciliationLoanForgiveness	1206000
CY2021	agen	Effective Income Tax Rate Reconciliation Loan Forgiveness EffectiveIncomeTaxRateReconciliationLoanForgiveness	-1301000
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	4565000
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	-12533000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	9242000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	4696000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3000000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2290000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-213000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-267000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-277000
CY2022	agen	Income Tax Reconciliation Income Tax Expense Benefit Change In Fair Value Of Contingent Consideration IncomeTaxReconciliationIncomeTaxExpenseBenefitChangeInFairValueOfContingentConsideration	-171000
CY2021	agen	Income Tax Reconciliation Income Tax Expense Benefit Change In Fair Value Of Contingent Consideration IncomeTaxReconciliationIncomeTaxExpenseBenefitChangeInFairValueOfContingentConsideration	2343000
CY2023	agen	Income Tax Reconciliation Expiration Of Tax Attributes IncomeTaxReconciliationExpirationOfTaxAttributes	14288000
CY2022	agen	Income Tax Reconciliation Expiration Of Tax Attributes IncomeTaxReconciliationExpirationOfTaxAttributes	10428000
CY2021	agen	Income Tax Reconciliation Expiration Of Tax Attributes IncomeTaxReconciliationExpirationOfTaxAttributes	571000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1188000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-3264000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-2650000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3291000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3148000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3614000
CY2023	agen	Unrecognized Tax Benefits Increase Decrease Related To Current Year Positions UnrecognizedTaxBenefitsIncreaseDecreaseRelatedToCurrentYearPositions	-6000
CY2022	agen	Unrecognized Tax Benefits Increase Decrease Related To Current Year Positions UnrecognizedTaxBenefitsIncreaseDecreaseRelatedToCurrentYearPositions	3000
CY2021	agen	Unrecognized Tax Benefits Increase Decrease Related To Current Year Positions UnrecognizedTaxBenefitsIncreaseDecreaseRelatedToCurrentYearPositions	-484000
CY2023	agen	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	148000
CY2022	agen	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	140000
CY2021	agen	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	18000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3433000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3291000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3148000
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14512000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	15872000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7101000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6946000
CY2023Q4	agen	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	7613000
CY2022Q4	agen	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	1848000
CY2023Q4	agen	Accrued Research Services Current AccruedResearchServicesCurrent	10807000
CY2022Q4	agen	Accrued Research Services Current AccruedResearchServicesCurrent	7074000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5250000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6519000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45283000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	38259000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.68
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	10457000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7952000
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3458000
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3505000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13915000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11457000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000
CY2023Q1	us-gaap	Dividends Payable Date Declared Day Month And Year DividendsPayableDateDeclaredDayMonthAndYear	2023-03-29
CY2023Q1	agen	Dividends Common Stock Shares DividendsCommonStockShares	5000000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2023-04-17
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.49
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.033
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	35984967
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.51
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10740187
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.22
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46750
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2528596
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.54
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1322597
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.5
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	42827211
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.25
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28097
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	42827211
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.25
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y5M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	28097
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	29002299
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.57
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.41
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.75
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.81
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	70000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4200000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	355802
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.5
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5381581
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.34
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4739888
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.45
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	454217
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.89
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	543278
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	11500000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	10900000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	5800000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22351000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18238000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19134000
CY2023Q4	agen	Estimate Of Payments For Clinical Trials EstimateOfPaymentsForClinicalTrials	645400000
CY2023	agen	Clinical Trials Expense ClinicalTrialsExpense	94500000
CY2022	agen	Clinical Trials Expense ClinicalTrialsExpense	66300000
CY2021	agen	Clinical Trials Expense ClinicalTrialsExpense	72800000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156314000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98024000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295665000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	13412000
CY2023	agen	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	30000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12281000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1161000
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	800000
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	10000000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	9351000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8878000
CY2023	agen	Finance Lease Cost FinanceLeaseCost	5024000
CY2022	agen	Finance Lease Cost FinanceLeaseCost	309000
CY2021	agen	Finance Lease Cost FinanceLeaseCost	407000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	3375000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	3108000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	1826000
CY2023	us-gaap	Sublease Income SubleaseIncome	0
CY2022	us-gaap	Sublease Income SubleaseIncome	613000
CY2021	us-gaap	Sublease Income SubleaseIncome	595000
CY2023	us-gaap	Lease Cost LeaseCost	18399000
CY2022	us-gaap	Lease Cost LeaseCost	12155000
CY2021	us-gaap	Lease Cost LeaseCost	10516000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2800000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2200000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2800000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2600000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2100000
CY2023	agen	Finance Lease Payments FinanceLeasePayments	8900000
CY2022	agen	Finance Lease Payments FinanceLeasePayments	500000
CY2021	agen	Finance Lease Payments FinanceLeasePayments	900000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29606000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31269000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29606000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31269000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2587000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1943000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62511000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	63326000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	65098000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	65269000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	35629000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	31764000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	35629000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	31764000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	10457000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7952000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4719000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	12270000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	15176000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	20222000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	6100000
CY2022	agen	Number Of Facility Leases NumberOfFacilityLeases	2
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9887000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	11669000
CY2023Q4	agen	Net Future Lease Commitments Payments Due Next Twelve Months NetFutureLeaseCommitmentsPaymentsDueNextTwelveMonths	21556000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10096000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	4831000
CY2023Q4	agen	Net Future Lease Commitments Payments Due Year Two NetFutureLeaseCommitmentsPaymentsDueYearTwo	14927000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9852000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	59000
CY2023Q4	agen	Net Future Lease Commitments Payments Due Year Three NetFutureLeaseCommitmentsPaymentsDueYearThree	9911000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10124000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2023Q4	agen	Net Future Lease Commitments Payments Due Year Four NetFutureLeaseCommitmentsPaymentsDueYearFour	10124000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10422000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2023Q4	agen	Net Future Lease Commitments Payments Due Year Five NetFutureLeaseCommitmentsPaymentsDueYearFive	10422000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	68916000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2023Q4	agen	Net Future Lease Commitments Payments Due After Year Five NetFutureLeaseCommitmentsPaymentsDueAfterYearFive	68916000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	119297000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	16559000
CY2023Q4	agen	Net Future Lease Commitments Payments Due NetFutureLeaseCommitmentsPaymentsDue	135856000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	54199000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1383000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	65098000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	15176000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y4M24D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.113
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.116
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	12914000
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	429000
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	13159000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13100000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13600000
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.84
CY2022Q4	agen	Price Per Share Premium To Average Closing Price Percentage PricePerSharePremiumToAverageClosingPricePercentage	0.15
CY2022Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Including Unamortized Transaction Costs LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesIncludingUnamortizedTransactionCosts	271560000
CY2023	agen	Non Cash Royalty And Milestone Revenue Recognized NonCashRoyaltyAndMilestoneRevenueRecognized	114572000
CY2023	agen	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	100308000
CY2023Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Including Unamortized Transaction Costs LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesIncludingUnamortizedTransactionCosts	257296000
CY2023Q4	agen	Liability Related To Sale Of Future Royalties Unamortized Transaction Costs LiabilityRelatedToSaleOfFutureRoyaltiesUnamortizedTransactionCosts	238000
CY2023Q4	agen	Liability Related To Sale Of Future Royalties And Milestones Net LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesNet	257058000
CY2023Q4	agen	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	300000
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	70485000
CY2023Q4	agen	Long Term Investments Fair Value Disclosure LongTermInvestmentsFairValueDisclosure	3222000
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	73707000
CY2023Q4	agen	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	318000
CY2023Q4	us-gaap	Nonfinancial Liabilities Fair Value Disclosure NonfinancialLiabilitiesFairValueDisclosure	318000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	164694000
CY2022Q4	agen	Short Term Investments Fair Value Disclosure ShortTermInvestmentsFairValueDisclosure	14684000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	179378000
CY2022Q4	agen	Contingent Consideration Liability Fair Value Disclosure ContingentConsiderationLiabilityFairValueDisclosure	874000
CY2022Q4	us-gaap	Nonfinancial Liabilities Fair Value Disclosure NonfinancialLiabilitiesFairValueDisclosure	874000
CY2023Q4	agen	Fair Value Transfers Into Or Out Of Level One And Level Two Amount FairValueTransfersIntoOrOutOfLevelOneAndLevelTwoAmount	0
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13100000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13600000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1300000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000
CY2023	us-gaap	Profit Loss ProfitLoss	-257437042
CY2022	ecd	Peo Total Comp Amt PeoTotalCompAmt	5626310
CY2022	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	-1356412
CY2022	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	969686
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156314000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98024000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295665000
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	142757000
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	137470000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Peo Total Comp Amt PeoTotalCompAmt	5856319
CY2023	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	-1232388
CY2023	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	1074363
CY2023	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	848288
CY2023	ecd	Total Shareholder Rtn Amt TotalShareholderRtnAmt	20.39
CY2023	ecd	Peer Group Total Shareholder Rtn Amt PeerGroupTotalShareholderRtnAmt	115.42
CY2022	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	1088774
CY2022	ecd	Total Shareholder Rtn Amt TotalShareholderRtnAmt	58.97
CY2022	ecd	Peer Group Total Shareholder Rtn Amt PeerGroupTotalShareholderRtnAmt	111.27
CY2022	us-gaap	Profit Loss ProfitLoss	-230655670
CY2021	ecd	Peo Total Comp Amt PeoTotalCompAmt	9757448
CY2021	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	8844707
CY2021	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	2809564
CY2021	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	2548466
CY2021	ecd	Total Shareholder Rtn Amt TotalShareholderRtnAmt	79.12
CY2021	ecd	Peer Group Total Shareholder Rtn Amt PeerGroupTotalShareholderRtnAmt	124.89
CY2021	us-gaap	Profit Loss ProfitLoss	-28723733
CY2020	ecd	Peo Total Comp Amt PeoTotalCompAmt	5637244
CY2020	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	-1572801
CY2020	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	1178911
CY2020	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	755519
CY2020	ecd	Total Shareholder Rtn Amt TotalShareholderRtnAmt	78.13
CY2020	ecd	Peer Group Total Shareholder Rtn Amt PeerGroupTotalShareholderRtnAmt	125.69
CY2020	us-gaap	Profit Loss ProfitLoss	-182891108
CY2023	ecd	Peo Name PeoName	Dr. Armen
CY2023	ecd	Peo Total Comp Amt PeoTotalCompAmt	5856319
CY2023	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	-1232388
CY2022	ecd	Peo Total Comp Amt PeoTotalCompAmt	5626310
CY2022	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	-1356412
CY2021	ecd	Peo Total Comp Amt PeoTotalCompAmt	9757448
CY2021	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	8844707
CY2020	ecd	Peo Total Comp Amt PeoTotalCompAmt	5637244
CY2020	ecd	Peo Actually Paid Comp Amt PeoActuallyPaidCompAmt	-1572801
CY2023	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	1074363
CY2023	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	848288
CY2022	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	969686
CY2022	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	1088774
CY2021	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	2809564
CY2021	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	2548466
CY2020	ecd	Non Peo Neo Avg Total Comp Amt NonPeoNeoAvgTotalCompAmt	1178911
CY2020	ecd	Non Peo Neo Avg Comp Actually Paid Amt NonPeoNeoAvgCompActuallyPaidAmt	755519
CY2023	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0000950170-24-031620-index-headers.html	Edgar Link	pending
0000950170-24-031620-index.html	Edgar Link	pending
0000950170-24-031620.txt	Edgar Link	pending
0000950170-24-031620-xbrl.zip	Edgar Link	pending
agen-20231231.htm	Edgar Link	pending
agen-20231231.xsd	Edgar Link	pending
agen-ex10_9a.htm	Edgar Link	pending
agen-ex21_1.htm	Edgar Link	pending
agen-ex23_1.htm	Edgar Link	pending
agen-ex31_1.htm	Edgar Link	pending
agen-ex31_2.htm	Edgar Link	pending
agen-ex32_1.htm	Edgar Link	pending
agen-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img189631100_0.jpg	Edgar Link	pending
img189631100_1.jpg	Edgar Link	pending
img189631100_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
agen-20231231_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGEN
AGENUS INC Stock $agen

2024 Q1 Form 10-K Financial Statement

#000095017024031620 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGEN AGENUS INC Stock $agen

2024 Q1 Form 10-K Financial Statement

#000095017024031620 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGEN
AGENUS INC Stock $agen